PMA
ATRC icon

Prudent Man Advisors’s AtriCure ATRC Stock Holding History

Prudent Man Advisors’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,248
Closed -$202K – 184
2025
Q1 		$202K Buy
+6,248
New +$232K 0.07% 162

Other funds holding ATRC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Prudent Man Advisors's ATRC Position: Q2 2025 in Review

Prudent Man Advisors sold out of AtriCure (ATRC) in Q2 2025, closing a stake of 6,248 shares — an estimated $202K sold.

Prudent Man Advisors first reported a position in ATRC in Q1 2025 and held it in 1 quarter. The position peaked at $202K in Q1 2025. 201 funds tracked by Wall St. Rank hold ATRC as of Q2 2025.

  • Prudent Man Advisors reported no remaining AtriCure position as of Q2 2025 after selling out during the quarter.
  • Prudent Man Advisors sold 6,248 AtriCure shares in Q2 2025, an estimated $202K.
  • Prudent Man Advisors first reported a position in AtriCure in Q1 2025 and held it in 1 quarter.
  • Prudent Man Advisors's AtriCure position peaked at $202K in Q1 2025.
  • 201 funds tracked by Wall St. Rank held AtriCure as of Q2 2025.

Based on Prudent Man Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.